NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement Monday, 6th January at 9:00 am •NeuroSense in Compliance with all Nasdaq Listing Requirements CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ --NeuroSense Therapeutics Ltd.(NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Company received formal written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's stockholders' equity requirement ("Equity Requirement") set forth in Nasdaq Listing Rule 5550(b)(1). The Company's Ordinary Shares will continue to be listed and trade on The Nasdaq Capital Market under the symbol "NRSN".
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.